EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Severe anaphylactic shock reaction upon rituximab rechallenge in membranous nephropathy: a case report and literature review

Weidong Huang, Yuanyuan Xu, XiaoXiao Jin, Qiankun Zhang, Tingyan Xiang, Wenhui Lei

Frontiers in Pharmacology · 29.05.2026 · 17

DOI: 10.3389/fphar.2026.1788362 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.05.2026. Verfasst von Weidong Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, China. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rituximab, an anti-CD20 monoclonal antibody, is an established treatment for primary membranous nephropathy (PMN). While generally well-tolerated, its recognized adverse effects include infusion-related reactions and immediate hypersensitivity. Particularly severe manifestations occurring >24 h post-infusion remain rarely reported. Case Presentation A 52-year-old male with a 7-year history of biopsy-proven PMN achieved complete remission after two uneventful courses of rituximab (1 g each) in 2018. He presented in August 2025 with nephrotic syndrome relapse. A third 1 g rituximab infusion was administered without immediate complications. Approximately 24 h post-infusion, he developed generalized urticaria, fever (38 °C), dysphagia, and arthralgia, progressing to hypotension (95/55 mmHg). Examination revealed diffuse, evanescent wheals. Laboratory findings showed elevated C-reactive protein, eosinophilia, and immunoglobulin E. Esophageal CT indicated localized wall edema, while infection was excluded. A diagnosis of severe hypersensitivity reaction (anaphylactic shock, acute urticaria, and angioedema) was made, consistent with Brown grade IV severity. He responded rapidly to intravenous methylprednisolone, antihistamines, and supportive care.

Conclusion

This report highlights the potential for life-threatening hypersensitivity upon rituximab re-challenge, even with a remote history of uneventful use. It emphasizes the need for prolonged post-infusion observation, patient education regarding delayed symptoms, and preparedness for immediate management of severe allergic phenomena. Further studies are warranted to elucidate risk factors and mechanisms underlying these rare but serious events.

Schlagwörter

Stichwörter der Autor:innen

adverse drug reactioncase reporthypersensitivity reactionmembranous nephropathyrituximab

Autor:innen und Institutionen

  • Department of Nephrology, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, China.
  • Department of Pathology,The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, China.
  • Department of Medicine, Liandu District Baiyun Street Community Health Service Center, Lishui, Zhejiang, China.
  • Department of Rheumatology, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, China.

Zitieren

APA

Huang, W., Xu, Y., Jin, X., Zhang, Q., Xiang, T., & Lei, W. (2026). Severe anaphylactic shock reaction upon rituximab rechallenge in membranous nephropathy: a case report and literature review. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1788362

Vancouver

Huang W, Xu Y, Jin X, Zhang Q, Xiang T, Lei W. Severe anaphylactic shock reaction upon rituximab rechallenge in membranous nephropathy: a case report and literature review. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1788362

BibTeX
@article{Huang2026,
  author = {Huang, Weidong and Xu, Yuanyuan and Jin, XiaoXiao and Zhang, Qiankun and Xiang, Tingyan and Lei, Wenhui},
  title = {Severe anaphylactic shock reaction upon rituximab rechallenge in membranous nephropathy: a case report and literature review},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1788362}
}
Kostenlos starten →